Pharmacodynamic, Pharmacokinetic, and Phase Ia Study of Bisthianostat, a Novel Histone Deacetylase Inhibitor, for the Treatment of Relapsed or Refractory Multiple Myeloma

Bisthianostat dose dependently induced acetylation of tubulin and H3 and increased PARP cleavage and apoptosis in RPMI-8226 cells. In RPMI-8226 and MM.1S cell xenograft mouse models, oral administration of bisthianostat for 18 days dose dependently inhibited tumor growth.